PHVS vs PPBT

Pharvaris N.V. vs Purple Biotech Ltd. — Valuation Comparison 2026

PHVS

Pharmaceutical Preparations
Pharvaris N.V.
Quality
3.9
out of 10
Value Trap
6
SAFE
Price
$30.16
Last close
Models
7/13
Active
VS

PPBT

Pharmaceutical Preparations
Purple Biotech Ltd.
Quality
3.6
out of 10
Value Trap
Price
$2.99
Last close
Models
2/13
Active

Model-by-Model Comparison

ModelType PHVS Fair ValuePHVS Upside PPBT Fair ValuePPBT Upside
Bayesian DCF Intrinsic $10.80 -64.2%
EROIC Spread Intrinsic $1.28 -57.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.30 -99.0% $0.54 -80.7%
Dynamic NAV Asset-Based $4.55 -84.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PHVS vs PPBT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PHVS vs PPBT — Which Stock Is More Undervalued?

PHVS scores higher with a 3.9/10 quality rating vs PPBT's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pharvaris N.V. (PHVS) and Purple Biotech Ltd. (PPBT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PHVS currently trades at $30.16 with a QOC of 3.9/10, while PPBT trades at $2.99 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).